Home LiteratureArticle Details
PMID: 14978129 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Recruitment of IFN-gamma-producing (Th1-like) cells into the inflamed retina in vivo is preferentially regulated by P-selectin glycoprotein ligand 1:P/E-selectin interactions.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 172 ·No. 5 ·2004-03-01 ·Pages 3215-24

Xu H, Manivannan A, Jiang HR, Liversidge J, Sharp PF, Forrester JV, Crane IJ

Abstract

Although there is evidence that altering the Th1/Th2 balance toward Th2 cells may be important in the resolution of Th1-type autoimmune disease, adoptive transfer of Th2 cells is not effective in protecting against Th1-type disease and may cause disease. Therefore, we examined the recruitment of Th1- and Th2-like cells into the retina in the murine autoimmune disease experimental autoimmune uveoretinitis. CD4 T cells were polarized in vitro to IFN-gamma-producing Th1-like cells and non-IFN-gamma-producing Th2-like cells, labeled, and adoptively transferred. Trafficking to the retina in vivo was evaluated by scanning laser ophthalmoscopy and infiltration by confocal microscopy. There were more rolling and adherent Th1-like cells and they rolled more slowly than did Th2-like cells. Th1-like cells were preferentially recruited into the retinal parenchyma at both initiation and resolution. Surface P-selectin glycoprotein ligand 1 (PSGL-1) and LFA-1 were up-regulated on both populations but were expressed at higher levels on Th1-like cells. Up-regulation of CD44 expression was higher on Th2-like cells. P-selectin, E-selectin, and ICAM-1 are up-regulated on postcapillary venules in the retina. Pretreatment of Th1-like cells with anti-PSGL-1 inhibited rolling and infiltration of Th1-like cells but not Th2-like cells, providing direct in vivo evidence for the inability of Th2 to respond to P/E-selectin despite increased expression of PSGL-1. Anti-LFA-1 pretreatment inhibited infiltration of both Th1- and Th2-like cells, but more so Th-1. We suggest that random trafficking of activated T cells (both Th1 and Th2) across the blood-retina barrier is mediated by CD44:CD44R and LFA-1:ICAM-1, whereas preferential recruitment of Th1 cells is mediated by PSGL-1:P/E-selectin.

MeSH Terms
Animals Autoimmune Diseases/immunology,pathology,physiopathology Blood-Retinal Barrier/immunology,metabolism,pathology Chemotaxis, Leukocyte/immunology Cytokines/biosynthesis,genetics E-Selectin/metabolism,physiology Endothelium, Vascular/immunology,metabolism,pathology Female Hyaluronan Receptors/physiology Hyaluronic Acid/physiology Intercellular Adhesion Molecule-1/biosynthesis Interferon-gamma/biosynthesis Ligands Lymphocyte Function-Associated Antigen-1/biosynthesis Membrane Glycoproteins/biosynthesis,metabolism,physiology Mice Mice, Inbred C57BL P-Selectin/biosynthesis,metabolism,physiology RNA, Messenger/biosynthesis Retina/immunology,metabolism,pathology Retinitis/immunology,pathology Th1 Cells/immunology,metabolism,pathology Uveitis/immunology,pathology
Chemicals
Cytokines E-Selectin Hyaluronan Receptors Ligands Lymphocyte Function-Associated Antigen-1 Membrane Glycoproteins P-Selectin P-selectin ligand protein RNA, Messenger Intercellular Adhesion Molecule-1 Interferon-gamma Hyaluronic Acid
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Xu Heping
Department of Ophthalmology, University of Aberdeen, Aberdeen, United Kingdom. [email protected]
Manivannan Ayyakkannu
Jiang Hui-Rong
Liversidge Janet
Sharp Peter F
Forrester John V
Crane Isabel J
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
2004-03-01
Pages
3215-24
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]